OR WAIT null SECS
March 08, 2024
EMA plans to add 10 partners to its real-world data initiative, DARWIN EU, in 2024.
March 07, 2024
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.
FDA has published final guidance documents regarding validation and development of analytical procedures.
New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.
Cellares CEO Fabian Gerlinghaus shares how an automated, closed-production platform with a small footprint can dramatically impact cost savings and scalability for cell and gene therapies.
March 06, 2024
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.
The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.
March 04, 2024
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
March 02, 2024
Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.
March 01, 2024
The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.